Denali Therapeutics (DNLI) Long-Term Investments (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Long-Term Investments data on file, last reported at $63.8 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $63.8 million, down 72.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $63.8 million (down 72.95% YoY), and the FY2025 annual result was $98.3 million, down 72.64% from the prior year.
• Long-Term Investments declined to $63.8 million in Q1 2026 per DNLI's latest filing, from $98.3 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $490.7 million in Q1 2024 and troughed at $7.9 million in Q3 2023.
• A 5-year average of $216.7 million and a median of $167.1 million in 2025 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2024 and 2025: Long-Term Investments jumped 5535.21% in 2024, then plunged 94.45% in 2025.
• A 5-year view of Long-Term Investments shows it stood at $94.2 million in 2022, then plunged by 91.61% to $7.9 million in 2023, then soared by 4446.15% to $359.4 million in 2024, then sank by 72.64% to $98.3 million in 2025, then slumped by 35.13% to $63.8 million in 2026.
• Business Quant data shows DNLI's Long-Term Investments at $63.8 million in Q1 2026, $98.3 million in Q4 2025, and $24.7 million in Q3 2025.